Challenges with drug efficacy prediction of in vitro models of biofilms infecting cystic fibrosis airway

References

• Cystic fibrosis Foundation Patient Registry 2021 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2021.
   Google Scholar
• Silva E, Monteiro R, Grainha T, et al. Fostering innovation in the treatment of chronic polymicrobial cystic fibrosis-associated infections exploring aspartic acid and succinic acid as ciprofloxacin adjuvants. Front Cell Infect Microbiol. 2020;10:10. doi: 10.3389/fcimb.2020.00441
   PubMed Web of Science ®Google Scholar
• Ghodake V, Dhoble S, Vavilala SL, et al. Anti-biofilm potential against P. aeruginosa biofilm in cystic fibrosis infection by systemically developed garlic extract incorporated liposomal formulation. J Drug Deliv Sci Technol. 2023;82:104359. doi: 10.1016/j.jddst.2023.104359
   Web of Science ®Google Scholar
• Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009 May 7;44(6):547–558. doi: 10.1002/ppul.21011
   PubMed Web of Science ®Google Scholar
• Kragh KN, Alhede M, Kvich L, et al. Into the well-A close look at the complex structures of a microtiter biofilm and the crystal violet assay. Biofilm. 2019;1:100006. doi: 10.1016/j.bioflm.2019.100006
   PubMedGoogle Scholar
• Yang L, Nilsson M, Gjermansen M, et al. Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation. Mol Microbiol. 2009;74(6):1380–1392. doi: 10.1111/j.1365-2958.2009.06934.x
   PubMed Web of Science ®Google Scholar
• la Fuente-Núñez C, Mansour SC, Wang Z, et al. Anti-biofilm and immunomodulatory activities of peptides that inhibit biofilms formed by pathogens isolated from cystic fibrosis patients. Antibiotics [Internet]. 2014;3:509–526. doi: 10.3390/antibiotics3040509
   Google Scholar
• Monteiro R, Magalhães AP, Pereira MO, et al. Long-term coexistence of Pseudomonas aeruginosa and staphylococcus aureus using an in vitro cystic fibrosis model. Future Microbiol. 2021;16(12):879–893. doi: 10.2217/fmb-2021-0025
   PubMed Web of Science ®Google Scholar
• Drevinek P, Holden MTG, Ge Z, et al. Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum. BMC Infect Dis. 2008;8(1):121. doi: 10.1186/1471-2334-8-121
   PubMedGoogle Scholar
• Sriramulu DD, Lunsdorf H, Lam JS, et al. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol. 2005;54(7):667–676. doi: 10.1099/jmm.0.45969-0
   PubMed Web of Science ®Google Scholar
• Palmer KL, Aye LM, Whiteley M. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol. 2007 Sep 18;189:8079–8087. doi: 10.1128/JB.01138-07
   PubMed Web of Science ®Google Scholar
• Turner KH, Wessel AK, Palmer GC, et al. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci USA. 2015;112(13):4110–4115. doi: 10.1073/pnas.1419677112
   PubMed Web of Science ®Google Scholar
• Kirchner S, Fothergill JL, Wright EA, et al. Use of artificial sputum medium to test antibiotic efficacy against pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp. 2012;(64):e3857. doi: 10.3791/3857
   PubMed Web of Science ®Google Scholar
• Cornforth DM, Dees JL, Ibberson CB, et al. Pseudomonas aeruginosa transcriptome during human infection. Proc Natl Acad Sci U S A. 2018;115(22):E5125–E5134. doi: 10.1073/pnas.1717525115
   PubMed Web of Science ®Google Scholar
• Harrington NE, Sweeney E, Harrison F. Building a better biofilm - formation of in vivo-like biofilm structures by Pseudomonas aeruginosa in a porcine model of cystic fibrosis lung infection. Biofilm. 2020;2:100024. doi: 10.1016/j.bioflm.2020.100024
   PubMedGoogle Scholar
• Sweeney E, Harrington NE, Harley Henriques AG, et al. An ex vivo cystic fibrosis model recapitulates key clinical aspects of chronic staphylococcus aureus infection. Microbiology. 2021;167(1):167. doi: 10.1099/mic.0.000987
   Web of Science ®Google Scholar
• Cidem A, Bradbury P, Traini D, et al. Modifying and integrating in vitro and ex vivo respiratory models for inhalation drug screening. Front Bioeng Biotechnol [Internet]. 2020;8. doi: 10.3389/fbioe.2020.581995
   PubMed Web of Science ®Google Scholar
• Plebani R, Potla R, Soong M, et al. Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip. J Cyst Fibros [Internet]. 2022;21(4):606–615. Available from: https://www.sciencedirect.com/science/article/pii/S1569199321021068
   PubMed Web of Science ®Google Scholar
• Wu Y, Romero M, Robertson SN, et al. Co-assembling living material as an in vitro lung epithelial infection model. Matter [Internet]. 2024;7:216–236. Available from: https://www.sciencedirect.com/science/article/pii/S2590238523005519
   Google Scholar
• OG A, Aurélie C, Rolf K, et al. Model systems to study the chronic, Polymicrobial Infections in Cystic fibrosis: Current approaches and exploring future directions. MBio. 2021;12(5). e01763–21. doi: 10.1128/mbio.01763-21
   PubMedGoogle Scholar
• Son MS, Matthews WJJ, Kang Y, et al. In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients. Infect Immun. 2007;75(11):5313–5324. doi: 10.1128/IAI.01807-06
   PubMed Web of Science ®Google Scholar
• Schaible B, Taylor CT, Schaffer K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob Agents Chemother. 2012;56(4):2114–2118. doi: 10.1128/AAC.05574-11
   PubMed Web of Science ®Google Scholar
• Van den BS, De BE, Coenye T, et al. The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects. Eur Respir Rev. 2021;30(161):210055. doi: 10.1183/16000617.0055-2021
   PubMed Web of Science ®Google Scholar